Literature DB >> 25192407

Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations.

Yves Reznik1, Suiying Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25192407      PMCID： PMC4201298          DOI： 10.1089/dia.2014.0261

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN： 1520-9156            Impact factor:   6.118


× No keyword cloud information.
  11 in total

1.  Clinical inertia in the management of Type 2 diabetes metabolic risk factors.

Authors:  R W Grant; E Cagliero; A K Dubey; C Gildesgame; H C Chueh; M J Barry; D E Singer; D M Nathan; J B Meigs
Journal:  Diabet Med       Date:  2004-02       Impact factor: 4.359

2.  Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies.

Authors:  T Tuomi; A Carlsson; H Li; B Isomaa; A Miettinen; A Nilsson; M Nissén; B O Ehrnström; B Forsén; B Snickars; K Lahti; C Forsblom; C Saloranta; M R Taskinen; L C Groop
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

Review 3.  Insulin pump therapy in adults.

Authors:  Triantafillos Didangelos; Fotios Iliadis
Journal:  Diabetes Res Clin Pract       Date:  2011-08       Impact factor: 5.602

4.  Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.

Authors:  Yves Reznik; Ohad Cohen; Ronnie Aronson; Ignacio Conget; Sarah Runzis; Javier Castaneda; Scott W Lee
Journal:  Lancet       Date:  2014-07-02       Impact factor: 79.321

5.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

6.  The burden of treatment failure in type 2 diabetes.

Authors:  Jonathan B Brown; Gregory A Nichols; Andrew Perry
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112

7.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2008-10-22       Impact factor: 10.122

8.  OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes-research design and methods.

Authors:  Ronnie Aronson; Ohad Cohen; Ignacio Conget; Sarah Runzis; Javier Castaneda; Simona de Portu; Scott Lee; Yves Reznik
Journal:  Diabetes Technol Ther       Date:  2014-04-15       Impact factor: 6.118

9.  Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK.

Authors:  A Rubino; L J McQuay; S C Gough; M Kvasz; P Tennis
Journal:  Diabet Med       Date:  2007-12       Impact factor: 4.359

10.  Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes.

Authors:  Matthew Riddle; Guillermo Umpierrez; Andres DiGenio; Rong Zhou; Julio Rosenstock
Journal:  Diabetes Care       Date:  2011-10-25       Impact factor: 19.112
View more
  4 in total

Review 1.  Keeping Up with the Diabetes Technology: 2016 Endocrine Society Guidelines of Insulin Pump Therapy and Continuous Glucose Monitor Management of Diabetes.

Authors:  Alfonso Galderisi; Elise Schlissel; Eda Cengiz
Journal:  Curr Diab Rep       Date:  2017-09-23       Impact factor: 4.810

2.  Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients.

Authors:  Feng-Fei Li; Bing-Li Liu; Guo-Ping Yin; Dan-Feng Zhang; Xiao-Fang Zhai; Mao-Yuan Chen; Xiao-Fei Su; Jin-Dan Wu; Lei Ye; Jian-Hua Ma
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

Review 3.  The OPT2MISE Study - A Review of the Major Findings and Clinical Implications.

Authors:  Yves Reznik; Michael Joubert
Journal:  Eur Endocrinol       Date:  2015-08-19

4.  Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion.

Authors:  Grazia Aleppo; Christopher G Parkin; Anders L Carlson; Rodolfo J Galindo; Davida F Kruger; Carol J Levy; Guillermo E Umpierrez; Gregory P Forlenza; Janet B McGill
Journal:  Diabetes Technol Ther       Date:  2021-06-17       Impact factor: 6.118
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.